Article Text

other Versions

Major improvements in Health-Related Quality of Life during the use of etanercept in patients with previously refractory Juvenile Idiopathic Arthritis
  1. Femke H M Prince (f.prince{at}
  1. Erasmus MC Sophia Children's Hospital, Netherlands
    1. Lianne M Geerdink (lgeerdink{at}
    1. Erasmus MC Sophia Children's Hospital, Netherlands
      1. Gerard J J M Borsboom (g.borsboom{at}
      1. Erasmus MC, Netherlands
        1. Marinka Twilt (m.twilt{at}
        1. Erasmus MC Sophia Children's Hospital, Netherlands
          1. Marion A J Van Rossum (m.a.vanrossum{at}
          1. Emma Children's Hospital AMC, Netherlands
            1. Esther P A H Hopppenreijs (e.hoppenreijs{at}
            1. Radboud University Nijmegen Medical Centre, Netherlands
              1. Rebecca ten Cate (r.ten_cate{at}
              1. LUMC, Netherlands
                1. Yvonne Koopman-Keemink (y.koopman{at}
                1. Hagaziekenhuis Juliana Children's Hospital, Netherlands
                  1. Marijke van Santen-Hoeufft (marijke.vansanten{at}
                  1. Academic Hospital Maastricht, Netherlands
                    1. Hein Raat (h.raat{at}
                    1. Erasmus MC, Netherlands
                      1. Lisette W A van Suijlekom-Smit (l.vansuijlekom{at}
                      1. Erasmus MC Sophia Children's Hospital, Netherlands


                        Objective: To evaluate changes in Health-Related Quality of Life (HRQoL) in patients with refractory Juvenile Idiopathic Arthritis (JIA) while treated with etanercept.

                        Methods: We included 53 JIA patients from seven Dutch centres. HRQoL was measured by the Childhood Health Assessment Questionnaire (CHAQ), Child Health Questionnaire (CHQ) and Health Utilities Index mark 3 (HUI3) at start and after 3, 15 and 27 months of treatment. At the same time points the following JIA disease activity variables were collected; physician’s global assessment through the Visual Analogue Scale (VAS), number of active and limited joints and erythrocyte sedimentation rate. Statistical method Linear Mixed Models was used to assess outcomes over time.

                        Results: During etanercept therapy HRQoL improved dramatically on both disease specific and generic HRQoL outcomes. Significant improvements were shown after three months and these improvements continued at least up to 27 months of treatment.

                        The disease specific CHAQ, including VAS pain and well-being, showed a significant improvement on all domains. The generic health-profile measure CHQ improved on all the health concepts except for "family cohesion", which was normal. The generic preference-based HUI3 showed impairment and subsequently significant improvement on the more specific domains ("pain", "ambulatory", "dexterity").

                        In accordance also disease activity variables improved significantly over time.

                        Conclusion: This study shows that HRQoL of patients with refractory JIA can substantially be improved by the use of etanercept on all aspects impaired by JIA. Information on HRQoL is crucial to understand the complete impact of etanercept treatment on JIA patients and their families.

                        Statistics from

                        Request permissions

                        If you wish to reuse any or all of this article please use the link below which will take you to the Copyright Clearance Center’s RightsLink service. You will be able to get a quick price and instant permission to reuse the content in many different ways.